The Impact of Median Model for End‐Stage Liver Disease at Transplant Minus 3 National Policy on Waitlist Outcomes in Patients With and Without Hepatocellular Carcinoma

Sarah Bernards, Ryutaro Hirose, Francis Y. Yao, Chengshi Jin, Jennifer L. Dodge, Chiung‐Yu Huang, Neil Mehta – 10 November 2021 – As a result of ongoing regional disparities, the United Network for Organ Sharing (UNOS) implemented policy in May 2019 limiting exception points for waitlisted patients with hepatocellular carcinoma (HCC) to median Model for End‐Stage Liver Disease at transplant in the area surrounding a transplant center minus 3 points (MMAT‐3). The impact of this policy change remains unknown.

Proposal and Validation of a Novel Scoring System for Hepatocellular Carcinomas Beyond Curability Borders

Coskun Ozer Demirtas, Gabrielle Ricco, Osman Cavit Ozdogan, Feyyaz Baltacioglu, Tunc Ones, Perran Fulden Yumuk, Ender Dulundu, Sinan Uzun, Pierro Colombatto, Filippo Oliveri, Maurizia Rosanna Brunetto, Feyza Gunduz – 8 November 2021 – Optimal scoring system for clinical prognostic factors in patients with unresectable hepatocellular carcinoma (HCC) is currently uncertain. We aimed to develop and externally validate an easy to use tool, particularly for this population, and named it the “unresectable hepatocellular carcinoma prognostic index” (UHPI).

Noninvasive Risk Stratification for Nonalcoholic Fatty Liver Disease Among Living Liver Donor Candidates: A Proposed Algorithm

Nilay Danis, Sharon R. Weeks, Ahyoung Kim, Azarakhsh Baghdadi, Maryam Ghadimi, Ihab R. Kamel, Behnam Saberi, Tinsay Woreta, Jacqueline Garonzik‐Wang, Benjamin Philosophe, Ahmet Gurakar, Rohit Loomba – 8 November 2021 – To reduce waitlist mortality, living donor liver transplantation (LDLT) has increased over the past decade in the United States, but not at a rate sufficient to completely mitigate organ shortage. As a result, there are ongoing efforts to expand the living liver donor pool.

Incidence and prediction of HBsAg seroclearance in a prospective multi‐ethnic HBeAg‐negative chronic hepatitis B cohort

Norah A. Terrault, Abdus S. Wahed, Jordan J. Feld, Stewart L. Cooper, Mark G. Ghany, Mauricio Lisker‐Melman, Robert Perrillo, Richard K. Sterling, Mandana Khalili, Raymond T. Chung, Philip Rosenthal, Robert J. Fontana, Arif Sarowar, Daryl T. Y. Lau, Junyao Wang, Anna S. Lok, Harry L. A. Janssen – 6 November 2021

Integrating Specialist Palliative Care in the Liver Transplantation Evaluation Process: A Qualitative Analysis of Hepatologist and Palliative Care Provider Views

Myrick C. Shinall, Kemberlee Bonnet, David Schlundt, Manisha Verma – 6 November 2021 – Patients undergoing evaluation for liver transplantation face heavy burdens of symptoms, health care use, and mortality. In other similarly ill populations, specialist palliative care has been shown to benefit patients, but specialist palliative care is infrequently used for liver transplantation patients. This project aims to describe the potential benefits of and barriers to specialist palliative care integration in the liver transplantation process.

Subscribe to